# Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

> **NCT03829410** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cardiff Oncology** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- KRAS Gene Mutation

## Interventions

- **DRUG:** Onvansertib
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT03829410
- **Lead sponsor:** Cardiff Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-24
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-01-29
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829410, "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03829410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*